Rizatriptan Benzoate
Product Images NDC 54868-6397

6 FDA label images from Physicians Total Care, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 54868-6397). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Rizatriptan Benzoate Orally Disintegrating Tablets 10 mg Bottle Labels (54868 6397 1)

Rizatriptan Benzoate Orally Disintegrating Tablets 10 mg Bottle Labels (54868 6397 1)
Rizatriptan 10 mg ODT (orally disintegrating tablet) label distributed by Physicians Total Care, Inc. The label shows the product name, strength, dosage form, NDC number 54868-6397-1, lot number, and expiration date, along with a barcode.*
FDA Label Image

Rizatriptan Benzoate Structural Formula (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 01)

Rizatriptan Benzoate Structural Formula (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 01)
Chemical structure of the active ingredient Rizatriptan Benzoate, showing its molecular framework including an indole group, a triazole ring, methylated amine group, and a benzoate moiety.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 02)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 02)
A line graph comparing the estimated probability of response over time (hours post-dose) for Rizatriptan Benzoate Tablets at 5 mg and 10 mg doses versus a placebo. The x-axis shows time from 0 to 2 hours post-dose and the y-axis shows the estimated probability of response from 0% to 100%. Both Rizatriptan doses show a higher probability of response than placebo over 2 hours, with 10 mg showing the greatest response.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 03)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 03)
A line graph showing estimated probability of remediation or rescue over 24 hours post-dose for Rizatriptan Benzoate Tablets 5 mg and 10 mg compared to placebo. The x-axis represents hours post-dose, and the y-axis shows probability percentage from 0% to 100%. Three lines represent placebo, 5 mg, and 10 mg dosages of Rizatriptan Benzoate Tablets.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 04)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 04)
A line graph plotting the estimated probability of response over hours post-dose. It compares placebo with Rizatriptan Benzoate Orally Disintegrating Tablets at 5 mg and 10 mg doses, with response probabilities increasing over 2 hours post-dose, showing higher response rates for the 10 mg dose.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 05)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 05)
A line chart showing the estimated probability of remediation or rescue over 24 hours post-dose. It compares Placebo, Rizatriptan Benzoate Orally Disintegrating Tablets 5 mg, and Rizatriptan Benzoate Orally Disintegrating Tablets 10 mg, with probability increasing over time on the y-axis and hours post-dose on the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.